A major obstacle in the successful implementation of gene-based therapies is the targeted distribution of the intended DNA to the cells of interest. To address the issue we develop an engineered strain of bacteria, which naturally dwell in the large intestine, capable of specific binding to and invasion of colorectal cancer cells and subsequent deposit of our circuit.